Krystal Biotech (NASDAQ:KRYS) Stock Keeps “Buy” Rating at HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $361.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 9.39% from the company’s previous close.

A number of other equities analysts have also recently issued reports on the company. Jefferies Financial Group reiterated a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a report on Monday, July 13th. Royal Bank Of Canada began coverage on Krystal Biotech in a report on Friday, August 14th. They issued an “outperform” rating and a $400.00 price objective for the company. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a report on Wednesday, September 23rd. Citigroup upped their price objective on Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Finally, Bank of America upped their price objective on Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and an average target price of $377.20.

Krystal Biotech Price Performance

KRYS stock traded down $0.69 during mid-day trading on Thursday, reaching $330.00. 288,016 shares of the company traded hands, compared to its average volume of 328,559. The company has a market capitalization of $9.77 billion, a P/E ratio of 41.35 and a beta of 0.50. Krystal Biotech has a 52-week low of $183.03 and a 52-week high of $382.54. The company has a fifty day moving average price of $340.61 and a 200-day moving average price of $323.20.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. The company had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. As a group, analysts forecast that Krystal Biotech will post 7.47 EPS for the current year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the transaction, the insider directly owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. This represents a 1.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino Rossi sold 25,000 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 13.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of KRYS. Terra Nova Asset Management LLC bought a new position in shares of Krystal Biotech during the third quarter valued at about $828,000. GK Wealth Management LLC bought a new position in shares of Krystal Biotech during the third quarter valued at about $59,000. GAMMA Investing LLC grew its stake in shares of Krystal Biotech by 10.2% during the third quarter. GAMMA Investing LLC now owns 1,100 shares of the company’s stock valued at $366,000 after buying an additional 102 shares during the last quarter. Toth Financial Advisory Corp grew its stake in shares of Krystal Biotech by 9.5% during the third quarter. Toth Financial Advisory Corp now owns 4,941 shares of the company’s stock valued at $1,643,000 after buying an additional 430 shares during the last quarter. Finally, Congress Asset Management Co. grew its stake in shares of Krystal Biotech by 34.8% during the third quarter. Congress Asset Management Co. now owns 54,083 shares of the company’s stock valued at $17,986,000 after buying an additional 13,949 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors designed to deliver functional genes to targeted tissues, with the goal of treating diseases caused by genetic mutations.

Krystal Biotech’s lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved in the United States for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.